Hundreds of lymphoma patients are set to benefit from the first chemotherapy-free treatment
Drugs watchdog NICE today approves NHS use of cutting-edge drug lenalidomide, which will benefit an estimated 900 cancer patients in England. (Source: the Mail online | Health)
Source: the Mail online | Health - February 27, 2020 Category: Consumer Health News Source Type: news
Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Peter Voorhees, MD Source Type: news
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news
Combination Therapy Induces High Response Among Relapsed/Refractory Follicular Lymphoma
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma
Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.The Cochrane Review used n...
Source: Cochrane News and Events - November 26, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news
Lenalidomide Slows Progression of Smoldering Multiple Myeloma Lenalidomide Slows Progression of Smoldering Multiple Myeloma
Early treatment with lenalidomide significantly delays the progression of smoldering multiple myeloma to symptomatic disease, according to the results of a randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Lenalidomide Delays Progression in Smoldering Multiple Myeloma
THURSDAY, Nov. 7, 2019 -- Lenalidomide significantly delays progression to symptomatic multiple myeloma in patients with smoldering multiple myeloma, according to a study published online Oct. 25 in the Journal of Clinical Oncology.
Sagar Lonial,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2019 Category: Pharmaceuticals Source Type: news
Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone. (Source: CancerNetwork)
Source: CancerNetwork - October 29, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news
Lenalidomide may delay onset of myeloma-related bone, organ damage
ROCHESTER Minn. -- The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 25, 2019 Category: Research Source Type: news
lenalidomide (Revlimid)
Title: lenalidomide (Revlimid)Category: MedicationsCreated: 3/25/2015 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news
Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
GALEN Study Examines Lenalidomide, Obinutuzumab Combo in Follicular Lymphoma
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - July 16, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
FDA Approves Daratumumab Combination For Multiple Myeloma
The FDA approved daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news
Janssen Announces U.S. FDA Approval of DARZALEX ® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 27, 2019 Category: Pharmaceuticals Source Type: news
